671 related articles for article (PubMed ID: 19704173)
21. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
[TBL] [Abstract][Full Text] [Related]
22. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.
Nogueira E; Ozaki KS; Tomiyama H; Granato CF; Camara NO; Pacheco-Silva A
Int Immunopharmacol; 2006 Dec; 6(13-14):2031-7. PubMed ID: 17161359
[TBL] [Abstract][Full Text] [Related]
23. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
24. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir.
Foulongne V; Turrière C; Diafouka F; Abraham B; Lastere S; Segondy M
Acta Virol; 2004; 48(1):51-5. PubMed ID: 15230476
[TBL] [Abstract][Full Text] [Related]
25. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
26. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
27. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
28. A deletion at CMV UL54 codon 524 without co-existing resistance-associated mutation at UL97 confers resistance to ganciclovir: A case report.
Green CB; O'Riordan A; Griffiths P; Haque T
J Clin Virol; 2016 Jul; 80():24-6. PubMed ID: 27131599
[TBL] [Abstract][Full Text] [Related]
29. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
[TBL] [Abstract][Full Text] [Related]
30. Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.
Campos AB; Ribeiro J; Pinho Vaz C; Campilho F; Branca R; Campos A; Baldaque I; Medeiros R; Boutolleau D; Sousa H
Antiviral Res; 2017 Feb; 138():86-92. PubMed ID: 27887982
[TBL] [Abstract][Full Text] [Related]
31. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Asberg A; Humar A; Jardine AG; Rollag H; Pescovitz MD; Mouas H; Bignamini A; Töz H; Dittmer I; Montejo M; Hartmann A;
Am J Transplant; 2009 May; 9(5):1205-13. PubMed ID: 19422345
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Bruminhent J; Rotjanapan P; Watcharananan SP
Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
[TBL] [Abstract][Full Text] [Related]
34. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.
Chou S; Boivin G; Ives J; Elston R
J Infect Dis; 2014 Apr; 209(8):1219-26. PubMed ID: 24273181
[TBL] [Abstract][Full Text] [Related]
36. Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.
Mousavi-Jazi M; Hökeberg I; Schloss L; Zweygberg-Wirgart B; Grillner L; Linde A; Brytting M
Transpl Infect Dis; 2001 Dec; 3(4):195-202. PubMed ID: 11844151
[TBL] [Abstract][Full Text] [Related]
37. Molecular Epidemiology of Cytomegalovirus UL97 and UL54 variants in Taiwan.
Yang SL; Lin TW; Lin HC; Wang HY; Chang PY; Wang PN; Yang S; Lu JJ
J Microbiol Immunol Infect; 2021 Oct; 54(5):971-978. PubMed ID: 33632621
[TBL] [Abstract][Full Text] [Related]
38. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
[TBL] [Abstract][Full Text] [Related]
39. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
[TBL] [Abstract][Full Text] [Related]
40. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
